Clinical Trials Browser

Phase 1/2 × Dasatinib × Sarcoma × Clear all

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00869401 2020-02-13

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1/2 Completed

217 enrolled 12 charts

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma